| 1 |
32393046 |
10.1080/09603123.2020.1757043 |
2022 |
The expression of microRNAs and exposure to environmental contaminants related to human health: a review. |
TP53 |
| 2 |
33297669 |
10.3324/haematol.2020.267294 |
2022 |
Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas. |
TP53 |
| 3 |
33954816 |
10.1007/s00277-021-04530-y |
2022 |
Venetoclax and decitabine in refractory TP53-mutated early T-cell precursor acute lymphoblastic leukemia. |
TP53 |
| 4 |
34092056 |
10.3324/haematol.2021.278304 |
2022 |
The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation. |
TP53 |
| 5 |
34226971 |
10.1007/s00428-021-03148-9 |
2022 |
Transdifferentiation of mantle cell lymphoma into sarcoma with limited neuromuscular differentiation after conventional chemotherapy. |
TP53 |
| 6 |
34244612 |
10.1038/s41375-021-01311-4 |
2022 |
Expression patterns and prognostic potential of circular RNAs in mantle cell lymphoma: a study of younger patients from the MCL2 and MCL3 clinical trials. |
TP53 |
| 7 |
34289655 |
10.3324/haematol.2021.278638 |
2022 |
Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome. |
TP53 |
| 8 |
34319003 |
10.1002/cnr2.1524 |
2022 |
Serum proteome modulations upon treatment provides biological insight on response to treatment in relapsed mantle cell lymphoma. |
TP53 |
| 9 |
34332791 |
10.1016/j.pathol.2021.04.008 |
2022 |
Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax. |
TP53 |
| 10 |
34365516 |
10.1007/s00262-021-03009-z |
2022 |
Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia. |
TP53 |
| 11 |
34467833 |
10.1080/10428194.2021.1973670 |
2022 |
CD5 expression in marginal zone lymphoma predicts differential response to rituximab or bendamustine/rituximab. |
TP53 |
| 12 |
34528662 |
10.1093/ajcp/aqab105 |
2022 |
MYC Expression Is Associated With p53 Expression and TP53 Aberration and Predicts Poor Overall Survival in Acute Lymphoblastic Leukemia/Lymphoma. |
TP53 |
| 13 |
34560683 |
10.1097/PAS.0000000000001813 |
2022 |
A Comprehensive Clinicopathologic and Molecular Study of 19 Primary Effusion Lymphomas in HIV-infected Patients. |
TP53 |
| 14 |
34592901 |
10.1080/10428194.2021.1983568 |
2022 |
Genetic profile of primary plasma cell leukemia in Korea: comparison with plasma cell myeloma. |
TP53 |
| 15 |
34597466 |
10.1002/pbc.29361 |
2022 |
Clonal dynamics in pediatric B-cell precursor acute lymphoblastic leukemia with very early relapse. |
TP53 |
| 16 |
34608246 |
10.1038/s41379-021-00909-4 |
2022 |
Blastoid high-grade B-cell lymphoma initially presenting in bone marrow: a diagnostic challenge. |
TP53 |
| 17 |
34664256 |
10.1111/bjh.17894 |
2022 |
Tracking the evolution of untreated high-intermediate/high-risk diffuse large B-cell lymphoma by circulating tumour DNA. |
TP53 |
| 18 |
34673251 |
10.1016/j.cbpc.2021.109215 |
2022 |
Environmentally relevant lead (Pb) water concentration induce toxicity in zebrafish (Danio rerio) larvae. |
TP53 |
| 19 |
34675373 |
10.1038/s41375-021-01444-6 |
2022 |
Genomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma. |
TP53 |
| 20 |
34687488 |
10.1002/gcc.23005 |
2022 |
Clinicopathological features and resistance mechanisms in HIP1-ALK-rearranged lung cancer: A multicenter study. |
TP53 |
| 21 |
34687742 |
10.1016/j.jid.2021.09.024 |
2022 |
PLCγ1/PKCθ Downstream Signaling Controls Cutaneous T-Cell Lymphoma Development and Progression. |
TP53 |
| 22 |
34690091 |
10.1016/j.clml.2021.09.013 |
2022 |
Clinical Characteristics, Prognosis, and Treatment Strategies of TP53 Mutations in Myelodysplastic Syndromes. |
TP53 |
| 23 |
34699592 |
10.1182/blood.2021011895 |
2022 |
Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. |
TP53 |
| 24 |
34710245 |
10.1002/ajh.26392 |
2022 |
Comprehensive analysis of TP53 mutation characteristics and identification of patients with inferior prognosis and enhanced immune escape in diffuse large B-cell lymphoma. |
TP53 |
| 25 |
34728235 |
10.1016/j.bbamcr.2021.119168 |
2022 |
DNA damage triggers an interplay between wtp53 and c-Myc affecting lymphoma cell proliferation and Kaposi sarcoma herpesvirus replication. |
TP53 |
| 26 |
34764434 |
10.1038/s41379-021-00962-z |
2022 |
BCL2 super-expressor diffuse large B-cell lymphoma: a distinct subgroup associated with poor prognosis. |
TP53 |
| 27 |
34788985 |
10.3324/haematol.2021.279631 |
2022 |
Mutational landscape of high-grade B-cell lymphoma with <i>MYC-</i>, <i>BCL2</i> and/or <i>BCL6</i> rearrangements characterized by whole-exome sequencing. |
TP53 |
| 28 |
34791836 |
10.1002/cam4.4422 |
2022 |
Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial. |
TP53 |
| 29 |
34799485 |
10.1097/PAS.0000000000001834 |
2022 |
Resistance of B-Cell Lymphomas to CAR T-Cell Therapy Is Associated With Genomic Tumor Changes Which Can Result in Transdifferentiation. |
TP53 |
| 30 |
34808593 |
10.1016/j.cancergen.2021.10.003 |
2022 |
Clinical utility of chromosomal microarray in establishing clonality and high risk features in patients with Richter transformation. |
TP53 |
| 31 |
34818414 |
10.1182/blood.2021012734 |
2022 |
Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in adult T-cell leukemia/lymphoma. |
TP53 |
| 32 |
34842019 |
10.1080/10428194.2021.2008383 |
2022 |
Fitting double-hit lymphoma into the aggressive lymphoma spectrum: a square peg in a round hole? |
TP53 |
| 33 |
34860572 |
10.1200/JCO.21.02143 |
2022 |
Impact of <i>TP53</i> Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy. |
TP53 |
| 34 |
34861096 |
10.1002/1878-0261.13153 |
2022 |
Mcl-1 and Bcl-xL levels predict responsiveness to dual MEK/Bcl-2 inhibition in B-cell malignancies. |
TP53 |
| 35 |
34861697 |
10.1182/bloodadvances.2021006156 |
2022 |
Epstein Barr virus-positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo. |
TP53 |
| 36 |
34882582 |
10.1172/JCI153283 |
2022 |
Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma. |
TP53 |
| 37 |
34907000 |
10.1124/molpharm.121.000354 |
2022 |
Senolytic-Mediated Elimination of Head and Neck Tumor Cells Induced Into Senescence by Cisplatin. |
TP53 |
| 38 |
34928233 |
10.5152/balkanmedj.2021.21068 |
2022 |
HOXD3 Up-regulating KDM5C Promotes Malignant Progression of Diffuse Large B-Cell Lymphoma by Decreasing p53 Expression |
TP53 |
| 39 |
34933652 |
10.1080/10428194.2021.2018579 |
2022 |
Prognostic scoring systems and risk stratification in myelodysplastic syndrome: focus on integration of molecular profile. |
TP53 |
| 40 |
34941996 |
10.1182/bloodadvances.2021005954 |
2022 |
Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma. |
TP53 |
| 41 |
34951009 |
10.1111/bjh.17971 |
2022 |
Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial. |
TP53 |
| 42 |
34980830 |
10.1097/PAS.0000000000001859 |
2022 |
Clinicopathologic and Genetic Features of Primary T-cell Lymphomas of the Central Nervous System: An Analysis of 11 Cases Using Targeted Gene Sequencing. |
TP53 |
| 43 |
34998786 |
10.1016/j.clml.2021.12.008 |
2022 |
The Application of NextGen Sequencing in the Diagnosis of Myeloid Neoplasms in Myeloma Patients With Cytopenia. |
TP53 |
| 44 |
35004079 |
10.7759/cureus.20914 |
2022 |
The Role of Tissue and Liquid Biopsy in the Clinical Management of Adult Lung Cancer Patients in King Abdul-Aziz Medical City in Riyadh, Saudi Arabia. |
TP53 |
| 45 |
35014928 |
10.1080/10428194.2021.2020779 |
2022 |
Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies. |
TP53 |
| 46 |
35030036 |
10.1200/JCO.21.02321 |
2022 |
Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial. |
TP53 |
| 47 |
35030632 |
10.1182/bloodadvances.2021006410 |
2022 |
Distinct clinical and genetic features of hepatitis B virus-associated follicular lymphoma in Chinese patients. |
TP53 |
| 48 |
35042152 |
10.1016/j.esmoop.2021.100333 |
2022 |
Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer. |
TP53 |
| 49 |
35047863 |
10.1016/j.xhgg.2021.100078 |
2022 |
A whole-exome case-control association study to characterize the contribution of rare coding variation to pancreatic cancer risk. |
TP53 |
| 50 |
35071774 |
10.1515/med-2021-0409 |
2022 |
The biomarkers of key miRNAs and gene targets associated with extranodal NK/T-cell lymphoma. |
TP53 |
| 51 |
35072373 |
10.1097/PPO.0000000000000573 |
2022 |
Checkpoint Inhibitors and Other Immune-Based Therapies in Acute Myeloid Leukemia. |
TP53 |
| 52 |
35091682 |
10.1038/s41388-022-02196-y |
2022 |
Potent, p53-independent induction of NOXA sensitizes MLL-rearranged B-cell acute lymphoblastic leukemia cells to venetoclax. |
TP53 |
| 53 |
35101379 |
10.1016/j.clml.2022.01.002 |
2022 |
Therapeutic Outcomes and Prognostic Impact of Gene Mutations Including TP53 and SF3B1 in Patients with Del(5q) Myelodysplastic Syndromes (MDS). |
TP53 |
| 54 |
35105854 |
10.1038/s41408-022-00617-5 |
2022 |
Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms. |
TP53 |
| 55 |
35106936 |
10.1002/cam4.4550 |
2022 |
SGK1 mutation status can further stratify patients with germinal center B-cell-like diffuse large B-cell lymphoma into different prognostic subgroups. |
TP53 |
| 56 |
35123209 |
10.1016/j.esmoop.2021.100337 |
2022 |
Real-world circulating tumor DNA analysis depicts resistance mechanism and clonal evolution in ALK inhibitor-treated lung adenocarcinoma patients. |
TP53 |
| 57 |
35130959 |
10.1186/s40364-022-00352-w |
2022 |
Haploidentical CD7 CAR T-cells induced remission in a patient with TP53 mutated relapsed and refractory early T-cell precursor lymphoblastic leukemia/lymphoma. |
TP53 |
| 58 |
35132678 |
10.1002/ajh.26490 |
2022 |
High prevalence and inferior long-term outcomes for TP53 mutations in therapy-related acute lymphoblastic leukemia. |
TP53 |
| 59 |
35151528 |
10.1016/j.blre.2022.100930 |
2022 |
CLL update 2022: A continuing evolution in care. |
TP53 |
| 60 |
35184869 |
10.1016/j.revmed.2022.01.010 |
2022 |
[Chronic lymphocytic leukemia]. |
TP53 |
| 61 |
35203244 |
10.3390/cells11040593 |
2022 |
Understanding Cell Lines, Patient-Derived Xenograft and Genetically Engineered Mouse Models Used to Study Cutaneous T-Cell Lymphoma. |
TP53 |
| 62 |
35231988 |
10.3760/cma.j.issn.0253-2727.2022.01.005 |
2022 |
[Mutational spectrum and its prognostic significance in childhood acute lymphoblastic leukemia based on next-generation sequencing technology]. |
TP53 |
| 63 |
35232479 |
10.1186/s13046-022-02269-6 |
2022 |
Partial p53 reactivation is sufficient to induce cancer regression. |
TP53 |
| 64 |
35237397 |
10.1177/20406207221080743 |
2022 |
Mantle cell lymphoma management trends and novel agents: where are we going? |
TP53 |
| 65 |
35240014 |
10.4143/crt.2022.017 |
2022 |
Circulating Tumor DNA-Based Genotyping and Monitoring for Predicting Disease Relapses of Patients with Peripheral T-Cell Lymphomas. |
TP53 |
| 66 |
35264779 |
10.1038/s41418-022-00964-7 |
2022 |
Flow cytometric single cell-based assay to simultaneously detect cell death, cell cycling, DNA content and cell senescence. |
TP53 |
| 67 |
35266562 |
10.1002/ajh.26523 |
2022 |
Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments. |
TP53 |
| 68 |
35277463 |
10.1136/jitc-2020-002029corr1 |
2022 |
Correction: MYC/BCL2/BCL6 triple hit and TP53 deletion in a case of high-grade B cell lymphoma receiving CAR T cell immunotherapy. |
TP53 |
| 69 |
35280362 |
10.21037/atm-22-412 |
2022 |
Genomic landscape and prognosis of patients with <i>TP53</i>-mutated non-small cell lung cancer. |
TP53 |
| 70 |
35280829 |
10.3389/fonc.2022.811151 |
2022 |
Prognostic Significance of Comprehensive Gene Mutations and Clinical Characteristics in Adult T-Cell Acute Lymphoblastic Leukemia Based on Next-Generation Sequencing. |
TP53 |
| 71 |
35301414 |
10.1038/s41379-022-01022-w |
2022 |
Nodal cytotoxic peripheral T-cell lymphoma occurs frequently in the clinical setting of immunodysregulation and is associated with recurrent epigenetic alterations. |
TP53 |
| 72 |
35327381 |
10.3390/biomedicines10030579 |
2022 |
Macrophage Infiltration Correlates with Genomic Instability in Classic Hodgkin Lymphoma. |
TP53 |
| 73 |
35344582 |
10.1182/blood.2021014007 |
2022 |
Extracellular vesicles and PD-L1 suppress macrophages, inducing therapy resistance in TP53-deficient B-cell malignancies. |
TP53 |
| 74 |
35356636 |
10.14740/jh942 |
2022 |
Concurrent Presentation of Hairy Cell Leukemia and Mantle Cell Lymphoma (Leukemic Non-Nodal Variant): An Extremely Rare Composite Lymphoma. |
TP53 |
| 75 |
35371098 |
10.3389/fimmu.2022.858590 |
2022 |
Identification of the Predictive Models for the Treatment Response of Refractory/Relapsed B-Cell ALL Patients Receiving CAR-T Therapy. |
TP53 |
| 76 |
35380239 |
10.1007/s00277-022-04806-x |
2022 |
The role of clonal hematopoiesis as driver of therapy-related myeloid neoplasms after autologous stem cell transplantation. |
TP53 |
| 77 |
35399106 |
10.1038/s41392-022-00924-0 |
2022 |
Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT. |
TP53 |
| 78 |
35417939 |
10.3324/haematol.2021.280352 |
2022 |
Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma. |
TP53 |
| 79 |
35426613 |
10.1007/s00432-022-04022-0 |
2022 |
Transformation of invasive lung adenocarcinoma with ALK rearrangement into pulmonary sarcomatoid carcinoma. |
TP53 |
| 80 |
35435617 |
10.1007/s11864-022-00953-5 |
2022 |
Chronic Lymphocytic Leukemia: Chemotherapy Free and Other Novel Therapies Including CAR T. |
TP53 |
| 81 |
35437610 |
10.1007/s00277-022-04795-x |
2022 |
Purine nucleoside analogs plus rituximab are an effective treatment choice for hairy cell leukemia-variant. |
TP53 |
| 82 |
35437925 |
10.1002/cam4.4663 |
2022 |
Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors. |
TP53 |
| 83 |
35452696 |
10.1016/j.humpath.2022.04.002 |
2022 |
B-cell lymphoma-2 downregulation is a useful feature supporting a neoplastic phenotype in mature T-cell lymphomas. |
TP53 |
| 84 |
35459873 |
10.1038/s41375-022-01571-8 |
2022 |
Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma. |
TP53 |
| 85 |
35486574 |
10.1371/journal.pone.0267543 |
2022 |
Anti-CD37 radioimmunotherapy with 177Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkin's lymphoma in vitro. |
TP53 |
| 86 |
35490155 |
10.1016/j.clml.2022.04.001 |
2022 |
Beyond BCL-2 Inhibition in Acute Myloid Leukemia: Other Approaches to Leverage the Apoptotic Pathway. |
TP53 |
| 87 |
35503707 |
10.1080/10428194.2022.2070911 |
2022 |
Rare case of leptomeningeal small lymphocytic lymphoma with <i>TP53</i> mutation detected by deep next-generation sequencing. |
TP53 |
| 88 |
35511481 |
10.1080/09553002.2022.2074164 |
2022 |
<i>BAG1, MGMT, FOXO1</i>, and <i>DNAJA1</i> as potential drug targets for radiosensitizing cancer cell lines. |
TP53 |
| 89 |
35533245 |
10.1158/2643-3230.BCD-21-0177 |
2022 |
Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma. |
TP53 |
| 90 |
35543621 |
10.1080/10428194.2022.2070913 |
2022 |
Predictive and prognostic value of gene mutations in myelodysplastic syndrome treated with hypomethylating agents: a meta-analysis. |
TP53 |
| 91 |
35551107 |
10.5045/br.2022.2020113 |
2022 |
Smudge cells in CD200<sup>+</sup>, <i>TP53</i> mutated leukemic mantle cell lymphoma. |
TP53 |
| 92 |
35551110 |
10.5045/br.2022.2022052 |
2022 |
Enrichment of TP53 alterations within GCB-like DNA subclassifications of diffuse large B-cell lymphoma after transition from de-novo to relapsed or refractory disease. |
TP53 |
| 93 |
35561299 |
10.1200/EDBK_349509 |
2022 |
New Directions for Mantle Cell Lymphoma in 2022. |
TP53 |
| 94 |
35561314 |
10.1182/bloodadvances.2022007247 |
2022 |
Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma. |
TP53 |
| 95 |
35562412 |
10.1038/s41379-022-01085-9 |
2022 |
Oncogenetic landscape of T-cell lymphoblastic lymphomas compared to T-cell acute lymphoblastic leukemia. |
TP53 |
| 96 |
35577753 |
10.1016/j.clml.2022.04.017 |
2022 |
SOHO State of the Art Updates and Next Questions | Management of Most Difficult Cases of Chronic Lymphocytic Leukemia: Relapse After Both BTK and BCL2 Inhibition and Richter Transformation. |
TP53 |
| 97 |
35579989 |
10.1002/ijc.34123 |
2022 |
Special issue The advance of solid tumor research in China: Real-world clinical outcomes of alectinib for advanced nonsmall-cell lung cancer patients with ALK fusion in China. |
TP53 |
| 98 |
35585141 |
10.1038/s41375-022-01587-0 |
2022 |
Pediatric T-ALL type-1 and type-2 relapses develop along distinct pathways of clonal evolution. |
TP53 |
| 99 |
35592333 |
10.3389/fimmu.2022.888250 |
2022 |
Aberrantly Activated APOBEC3B Is Associated With Mutant p53-Driven Refractory/Relapsed Diffuse Large B-Cell Lymphoma. |
TP53 |
| 100 |
35592856 |
10.3389/fmed.2022.808378 |
2022 |
A Somatic Mutation Signature Predicts the Best Overall Response to Anti-programmed Cell Death Protein-1 Treatment in Epidermal Growth Factor Receptor/Anaplastic Lymphoma Kinase-Negative Non-squamous Non-small Cell Lung Cancer. |
TP53 |
Datasets
Models
